Table 1.
Summary of Retrospective and Prospective Trials/Registries of Extracranial MRT
| Number of Patients, (Localisation) | Median Age (Months) | Advanced Stage (%)§ | Prognostic Factors | OS (Years) | EFS (Years) | References | |
|---|---|---|---|---|---|---|---|
| NWTSG 1,2,3,4,5 | 142 (RTK=142) | 10.6 (0–8 years) | 31% 44/142 | age, stage, CNS involvement | 23.2% (4 year) | n.a. | [8] |
| SIOP RTSG | 107 (RTK=107) | 13 (0–9 years) | 25% 27/107 | age, stage | 26% (5 year) | 22% (5 year) | [9] |
| SEER | 229 (ATRT=81, eMRT=103, RTK=45) | 24 (0–89 years) | 43% 58/134* | age, stage, RTx | 33% (5 year)** | n.a. | [32] |
| EpSSG NRSTS 2005 | 100 (eMRT=83, RTK=17) | 16.8 (3 d - 10.9 years) | 23% 23/100 | age, gender*** | 38.4% (3 year) | 32.3% (3 year) | [10] |
| Beijing Children’s Hospital | 53 (eMRT=21, RTK=32) | 16 (0–8.75) | 36% (19/53) | age, stage | 23.7% (3 year) | 14.5% (3 year) | [34] |
| EU-RHAB | 100 (eMRT=70, RTK=30) | 11.6 (0–17.2 years) | 35% 35/100 | GLM, stage, surgery | 45.8% (5 year) | 35.2% (5 year) | [6] |
Notes: §Distant metastasis or synchronous tumor, *n=14 patients without staging not included, **5-year OS for entire group of patients, ***Only in patients with advanced stage.